• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用分子诊断和组织学作为确证手段,结合供体游离 DNA 片段和数量检测来诊断肾移植排斥反应。

Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation.

机构信息

Alberta Transplant Applied Genomics Centre, Edmonton, University of Alberta, Canada.

Natera Inc, San Carlos, CA.

出版信息

Transplantation. 2022 Dec 1;106(12):2435-2442. doi: 10.1097/TP.0000000000004212. Epub 2022 Nov 22.

DOI:10.1097/TP.0000000000004212
PMID:35765145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9698190/
Abstract

BACKGROUND

Donor-derived cell-free DNA (dd-cfDNA) fraction and quantity have both been shown to be associated with allograft rejection. The present study compared the relative predictive power of each of these variables to the combination of the two, and developed an algorithm incorporating both variables to detect active rejection in renal allograft biopsies.

METHODS

The first 426 sequential indication biopsy samples collected from the Trifecta study ( ClinicalTrials.gov # NCT04239703) with microarray-derived gene expression and dd-cfDNA results were included. After exclusions to simulate intended clinical use, 367 samples were analyzed. Biopsies were assessed using the molecular microscope diagnostic system and histology (Banff 2019). Logistic regression analysis examined whether combining dd-cfDNA fraction and quantity adds predictive value to either alone. The first 149 sequential samples were used to develop a two-threshold algorithm and the next 218 to validate the algorithm.

RESULTS

In regression, the combination of dd-cfDNA fraction and quantity was found to be significantly more predictive than either variable alone ( P = 0.009 and P < 0.0001). In the test set, the area under the receiver operating characteristic curve of the two-variable system was 0.88, and performance of the two-threshold algorithm showed a sensitivity of 83.1% and specificity of 81.0% for molecular diagnoses and a sensitivity of 73.5% and specificity of 80.8% for histology diagnoses.

CONCLUSIONS

This prospective, biopsy-matched, multisite dd-cfDNA study in kidney transplant patients found that the combination of dd-cfDNA fraction and quantity was more powerful than either dd-cfDNA fraction or quantity alone and validated a novel two-threshold algorithm incorporating both variables.

摘要

背景

供体来源的无细胞 DNA(dd-cfDNA)片段和数量均与移植物排斥反应相关。本研究比较了这些变量各自以及两者组合对预测移植物排斥反应的相对能力,并建立了一个结合两种变量的算法,以检测肾移植活检中的活跃排斥反应。

方法

纳入了 Trifecta 研究(ClinicalTrials.gov # NCT04239703)中首次使用微阵列衍生的基因表达和 dd-cfDNA 结果的前 426 例序贯指示性活检样本。排除后,模拟预期的临床使用,共分析了 367 例样本。使用分子显微镜诊断系统和组织学(Banff 2019)评估活检。使用逻辑回归分析检查了 dd-cfDNA 片段和数量的组合是否比单独使用其中任何一个变量更具预测价值。前 149 例连续样本用于开发两阈值算法,接下来的 218 例样本用于验证算法。

结果

在回归中,dd-cfDNA 片段和数量的组合被发现比单独使用任何一个变量都更具预测性(P=0.009 和 P<0.0001)。在测试集中,两变量系统的接受者操作特征曲线下面积为 0.88,两阈值算法的性能显示出对分子诊断的敏感性为 83.1%和特异性为 81.0%,对组织学诊断的敏感性为 73.5%和特异性为 80.8%。

结论

本前瞻性、活检匹配、多中心的肾移植患者 dd-cfDNA 研究发现,dd-cfDNA 片段和数量的组合比单独使用 dd-cfDNA 片段或数量更具预测能力,并验证了一种新的结合两种变量的两阈值算法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/90bb8f159e02/tp-106-2435-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/b0a3a8af520f/tp-106-2435-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/e6131dc95a9d/tp-106-2435-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/51cce0a1fef1/tp-106-2435-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/90bb8f159e02/tp-106-2435-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/b0a3a8af520f/tp-106-2435-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/e6131dc95a9d/tp-106-2435-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/51cce0a1fef1/tp-106-2435-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/180f/9698190/90bb8f159e02/tp-106-2435-g004.jpg

相似文献

1
Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation.采用分子诊断和组织学作为确证手段,结合供体游离 DNA 片段和数量检测来诊断肾移植排斥反应。
Transplantation. 2022 Dec 1;106(12):2435-2442. doi: 10.1097/TP.0000000000004212. Epub 2022 Nov 22.
2
The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies.三因素研究:比较供体游离 DNA 水平与肾移植活检分子表型。
J Am Soc Nephrol. 2022 Feb;33(2):387-400. doi: 10.1681/ASN.2021091191. Epub 2022 Jan 20.
3
Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-kidney Transplantation.供者游离 DNA 对胰肾联合移植后排斥反应的诊断具有高灵敏度。
Transplantation. 2022 Aug 1;106(8):1690-1697. doi: 10.1097/TP.0000000000004088. Epub 2022 Mar 14.
4
Comparing Plasma Donor-derived Cell-free DNA to Gene Expression in Endomyocardial Biopsies in the Trifecta-Heart Study.比较三尖瓣心脏研究中血浆供体游离 DNA 与心肌活检基因表达。
Transplantation. 2024 Sep 1;108(9):1931-1942. doi: 10.1097/TP.0000000000004986. Epub 2024 Aug 20.
5
Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients.联合血液基因表达和循环游离 DNA 检测诊断肾移植受者亚临床排斥反应。
Clin J Am Soc Nephrol. 2021 Oct;16(10):1539-1551. doi: 10.2215/CJN.05530421.
6
Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study.作为肾移植排斥反应和移植物损伤标志物的供体游离 DNA 绝对定量:前瞻性观察研究结果。
Am J Transplant. 2019 Nov;19(11):3087-3099. doi: 10.1111/ajt.15416. Epub 2019 May 28.
7
Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study.抗体介导的排斥反应在检测不到供体特异性抗体时释放供体细胞游离 DNA:Trifecta 研究的结果。
Transplantation. 2023 Mar 1;107(3):709-719. doi: 10.1097/TP.0000000000004324. Epub 2023 Feb 21.
8
Donor-derived cell-free DNA (dd-cfDNA) for detection of allograft rejection in pediatric kidney transplants.供体来源的无细胞 DNA(dd-cfDNA)在儿科肾移植中的同种异体排斥检测。
Pediatr Transplant. 2021 Mar;25(2):e13850. doi: 10.1111/petr.13850. Epub 2020 Nov 20.
9
Donor-derived cell-free DNA predicted allograft rejection and severe microvascular inflammation in kidney transplant recipients.供者来源的无细胞 DNA 可预测肾移植受者的移植物排斥和严重的微血管炎症。
Front Immunol. 2024 Jul 9;15:1433918. doi: 10.3389/fimmu.2024.1433918. eCollection 2024.
10
Diagnostic Performance of Donor-Derived Plasma Cell-Free DNA Fraction for Antibody-Mediated Rejection in Post Renal Transplant Recipients: A Prospective Observational Study.供体源性浆细胞游离 DNA 片段在肾移植受者抗体介导排斥反应中的诊断性能:一项前瞻性观察研究。
Front Immunol. 2020 Feb 28;11:342. doi: 10.3389/fimmu.2020.00342. eCollection 2020.

引用本文的文献

1
Novel Biomarkers for Rejection in Kidney Transplantation: A Comprehensive Review.肾移植排斥反应的新型生物标志物:综述
J Clin Med. 2025 Aug 4;14(15):5489. doi: 10.3390/jcm14155489.
2
Donor-derived cell-free DNA and miRNA monitoring for the early prediction and diagnosis of liver allograft rejection and patient outcomes.供体来源的游离DNA和微小RNA监测用于肝移植排斥反应及患者预后的早期预测和诊断。
Front Immunol. 2025 Jun 24;16:1604200. doi: 10.3389/fimmu.2025.1604200. eCollection 2025.
3
Using a combination of biomarkers to monitor allograft dysfunction in lung transplant recipients.
联合使用生物标志物监测肺移植受者的移植物功能障碍。
Front Transplant. 2025 May 8;4:1574898. doi: 10.3389/frtra.2025.1574898. eCollection 2025.
4
A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes.一项关于上皮细胞损伤在肾移植结局中作用的横断面研究。
JCI Insight. 2025 Apr 15;10(10). doi: 10.1172/jci.insight.188658. eCollection 2025 May 22.
5
Combination Automated Microfluidics Measurement of Urine C-C Motif Ligand 2, CXC-Motif Chemokine 9, CXC-Motif Chemokine 10, and Vascular Endothelial Growth Factor A for Monitoring Patients with a Kidney Transplant.联合自动微流控法检测尿C-C基序配体2、CXC基序趋化因子9、CXC基序趋化因子10和血管内皮生长因子A用于监测肾移植患者
Clin J Am Soc Nephrol. 2025 May 1;20(5):719-732. doi: 10.2215/CJN.0000000666. Epub 2025 Mar 11.
6
Donor-derived cell-free DNA for detection of acute rejection in lung transplant recipients.供体来源的游离DNA用于检测肺移植受者的急性排斥反应。
Front Immunol. 2025 Jan 29;16:1531774. doi: 10.3389/fimmu.2025.1531774. eCollection 2025.
7
Integrating Donor Derived Cell-Free DNA Fraction and Absolute Quantification for Enhanced Rejection Diagnosis in Kidney Transplant Recipients.整合供体来源的游离DNA片段和绝对定量以增强肾移植受者的排斥反应诊断
Diagnostics (Basel). 2025 Jan 21;15(3):237. doi: 10.3390/diagnostics15030237.
8
Evaluation of donor specific antibodies after kidney transplantation in the era of donor-derived cell-free DNA.供体来源游离DNA时代肾移植后供体特异性抗体的评估
Front Immunol. 2025 Jan 16;15:1530065. doi: 10.3389/fimmu.2024.1530065. eCollection 2024.
9
Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial.供体来源的游离DNA监测用于肾移植后抗体介导排斥反应的早期诊断:一项随机试验
Nephrol Dial Transplant. 2024 Nov 29. doi: 10.1093/ndt/gfae282.
10
Biomarkers of Rejection in Kidney Transplantation.肾移植排斥反应的生物标志物
Am J Kidney Dis. 2025 Mar;85(3):364-374. doi: 10.1053/j.ajkd.2024.07.018. Epub 2024 Oct 16.